Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
24.05
-0.51 (-2.08%)
At close: Oct 23, 2026, 4:00 PM EDT
23.83
-0.22 (-0.91%)
After-hours: Oct 23, 2026, 7:52 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 540 employees as of June 30, 2026. The number of employees increased by 31 or 6.09% compared to the same quarter last year. That makes Beam Therapeutics the 19,503rd largest employer in the world and 2,634th in the United States.
Employees
540
Change (1Y)
31
Growth (1Y)
6.09%
Revenue / Employee
$288,954
Profits / Employee
-$160,222
Market Cap
2.40B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 540 | 31 | 6.09% |
| Mar 31, 2026 | 522 | 129 | 32.82% |
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| ADMA Biologics | 647 |
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Viridian Therapeutics | 252 |
| Celldex Therapeutics | 198 |
| Precigen | 160 |
| Aurinia Pharmaceuticals | 128 |
BEAM News
- 11 days ago - Beam Therapeutics to present initial BEAM-301 data at ESGCT - TheFly
- 11 days ago - Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress - GlobeNewsWire
- 4 weeks ago - Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today - TheFly
- 4 weeks ago - Cathie Wood’s ARK Investment buys 103K shares of Beam Therapeutics today - TheFly
- 5 weeks ago - BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
- 6 weeks ago - Beam Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - Cathie Wood’s ARK Investment buys 271K shares of Beam Therapeutics today - TheFly
- 6 weeks ago - Beam Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts